Pregled bibliografske jedinice broj: 1160946
Catestatin as a Biomarker of Cardiovascular Diseases: A Clinical Perspective
Catestatin as a Biomarker of Cardiovascular Diseases: A Clinical Perspective // Biomedicines, 9 (2021), 12; 1757, 14 doi:10.3390/biomedicines9121757 (međunarodna recenzija, pregledni rad, znanstveni)
CROSBI ID: 1160946 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Catestatin as a Biomarker of Cardiovascular
Diseases: A Clinical Perspective
Autori
Bozic, Josko ; Kumric, Marko ; Ticinovic Kurir, Tina ; Urlic, Hrvoje ; Martinovic, Dinko ; Vilovic, Marino ; Tomasovic Mrcela, Nada ; Borovac, Josip A.
Izvornik
Biomedicines (2227-9059) 9
(2021), 12;
1757, 14
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni
Ključne riječi
catestatin ; cardiovascular disease ; ChgA ; chromogranin ; sympathetic nervous system ; heart failure ; ischemia-reperfusion injury ; review
Sažetak
Accounting for almost one-third of the global mortality, cardiovascular diseases (CVDs) represent a major global health issue. Emerging data suggest that most of the well-established mechanistic explanations regarding the cardiovascular pathophysiology are flawed, and cannot fully explain the progression and long-term effects of these diseases. On the other hand, dysregulation of the sympathetic nervous system (SNS) has emerged as an important player in the pathophysiology of CVDs. Even though upregulated SNS activity is an essential compensatory response to various stress conditions, in the long term, it becomes a major contributor to both cardiac dysfunction and vascular damage. Despite the fact that the importance of SNS hyperactivity in the setting of CVDs has been well-appreciated, its exact quantification and clinical application in either diagnostics or therapy of CVDs is still out of reach. Nevertheless, in recent years a number of novel laboratory biomarkers implicated in the pathophysiology of SNS activation have been explored. Specifically, in this review, we aimed to discuss the role of catestatin, a potent physiological inhibitor of catecholamine spillover that offers cardioprotective effects. Limited data indicate that catestatin could also be a reliable indirect marker of SNS activity and it is likely that high CST levels reflect advanced CV disease burden. Consequently, large-scale studies are required to validate these observations in the upcoming future.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Nastavni zavod za javno zdravstvo "Dr. Andrija Štampar",
KBC Split,
Medicinski fakultet, Split,
Sveučilište u Splitu Sveučilišni odjel zdravstvenih studija
Profili:
Marino Vilović
(autor)
Marko Kumrić
(autor)
Nada Tomasović Mrčela
(autor)
Josip Anđelo Borovac
(autor)
Tina Tičinović Kurir
(autor)
Joško Božić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus